Lunit Cancer Screening published a study evaluating whether Lunit INSIGHT MMG correctly localized lesions in interval cancer cases.
Public source
Publisher name
Public post
Using an AI tool that marks a lesion is one thing. Using a tool proven to focus attention on the marks that matter is another. 🔍 A recent Radiology study evaluated not…
Company
Lunit Cancer Screening
- Industry
- Software Development
- Location
- Seattle, US
- Company size
- 201–500 employees
About Lunit Cancer Screening
Conquer Cancer through AI. Lunit is a public company that develops medical AI software for cancer screening and treatment. Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally. < Lunit AI Suite for Radiology > • Lunit INSIGHT CXR, AI Solution for Chest X-ray • Lunit INSIGHT MMG, AI Solution for Mammography • Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis • Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only *If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.
See moreLatest activity
Latest activity from Lunit Cancer Screening
4 signals
Presence & Recognition
Lunit Cancer Screening is participating in the inaugural BRiM Summit 2026, which is scheduled for September 15–17, 2026, at The University of Western Australia.
Research & Knowledge
Lunit Cancer Screening published the latest issue of the Squeeze, which digs into evidence, context, and real-world experiences behind breast imaging conversations, including AI coworker studies, automation bias studies, AI-stream insights, and 10 considerations for a future-ready screening ecosystem.
Presence & Recognition
Lunit Cancer Screening participated in the AOCR-SGCR 2026 event in Singapore.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Lunit
Lunit published an August Medium article on cancer care challenges and AI applications in screening and diagnosis using the World Health Organization Global Status Report on Cancer 2026.
Research & Knowledge
Panakeia
Panakeia published a new peer-reviewed study validating PANProfiler Breast ER, PR, and HER2 status directly from routine pathology images in collaboration with clinical partners, published in Clinical Breast Cancer.
Research & Knowledge
Radiology News
Radiology News published a study following 1,975 women across 3,037 abbreviated breast MRI examinations to assess screening performance over three consecutive years.
Research & Knowledge
iPro, Inc.
iPro, Inc. published a longitudinal DBT study that could help improve long-term breast cancer risk prediction via AuntMinnie.com, American Journal of Roentgenology, and NYU Langone Health.
Research & Knowledge
ScreenPoint Medical